Marketing authorization procedures for advanced cancer drugs: exploring the views of patients, oncologists, healthcare decision makers and citizens in France

Christel Protiere*, Rachel Baker, Dominique Genre, Anthony Goncalves, Patrice Viens

*Corresponding author for this work

Research output: Contribution to journalArticle

82 Downloads (Pure)

Abstract

Background: The past decades have seen advances in cancer treatments in terms of toxicity and side effects but progress in the treatment of advanced cancer has been modest. New drugs have emerged improving progression free survival but with little impact on overall survival, raising questions about the criteria on which to base decisions to grant marketing authorizations and about the authorization procedure itself. For decisions to be fair, transparent and accountable, it is necessary to consider the views of those with relevant expertise and experience.
Methods: We conducted a Q-study to explore the views of a range of stakeholders in France, involving: 54 patients (18 months after diagnosis); 50 members of the general population; 27 oncologists; 19 healthcare decision makers; and 2 individuals from the pharmaceutical industry.
Results: Three viewpoints emerged, focussing on different dimensions entitled: 1) ‘Quality of life (QoL), opportunity cost and participative democracy’; 2)‘QoL and patient-centeredness’; and 3) ‘Length of life’. Respondents from all groups were associated with each viewpoint, except for healthcare decision makers, who were only associated with the first one.
Conclusion: Our results highlight plurality in the views of stakeholders, emphasize the need for transparency in decision making processes, and illustrate the importance of a re-evaluation of treatments for all 3 viewpoints. In the context of advanced cancer, our results suggest that QoL should be more prominent amongst authorization criteria, as it is a concern for 2 of the 3 viewpoints.
Original languageEnglish
Pages (from-to)555-566
Number of pages12
JournalMedical Decision Making
Volume37
Issue number5
Early online date15 Feb 2017
DOIs
Publication statusPublished - 1 Jul 2017

Keywords

  • cancer
  • cancer treatment
  • social values
  • Q methodology
  • marketing authorisation
  • France

Fingerprint Dive into the research topics of 'Marketing authorization procedures for advanced cancer drugs: exploring the views of patients, oncologists, healthcare decision makers and citizens in France'. Together they form a unique fingerprint.

  • Profiles

    Cite this